← Back to Search

Procedure

TFLEP vs m-HoLEP for Enlarged Prostate

N/A
Recruiting
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with symptomatic benign prostate hyperplasia : urinary retention, acute renal failure (post-renal), refractory hematuria, repeated urinary tract infections, refractory symptoms.
Prostates between 50-300 grams,
Must not have
History of prostatic surgery,
Patients unfit for surgery
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1-year post-operatively
Awards & highlights
No Placebo-Only Group

Summary

This trial compares two laser treatments for men with enlarged prostates causing urinary problems. It aims to see which laser method, holmium with Moses technology or thulium fiber, is safer and more effective. The study will help doctors choose the best treatment for their patients.

Who is the study for?
Men with bothersome urinary symptoms due to an enlarged prostate (BPH), who haven't improved with medication, can join. They should have a prostate size between 50-300 grams and a urine flow rate of less than 15 ml/sec. Men who've had previous prostate/bladder surgery, cancer in these areas, or certain bladder conditions cannot participate.
What is being tested?
The study compares two laser technologies for treating BPH: m-HoLEP uses the Ho: YAG laser with Moses technology for better blood control; TFLEP uses thulium fiber laser which may offer similar benefits. The trial will assess safety and effectiveness up to one year after treatment.
What are the potential side effects?
Potential side effects from both procedures include bleeding, infection risk, temporary difficulty urinating or need for catheterization post-surgery, irritation during urination, erectile dysfunction, and rare cases of urinary incontinence.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have severe symptoms from an enlarged prostate, like difficulty urinating or kidney issues.
Select...
My prostate weighs between 50-300 grams.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had surgery on my prostate.
Select...
I am not a candidate for surgery due to my health condition.
Select...
I have a history of prostate or bladder cancer.
Select...
I am on blood thinners, but I can't stop them for surgery.
Select...
I have a narrowed urethra.
Select...
I have a condition where my bladder doesn't empty properly due to nerve problems.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1-year post-operatively
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1-year post-operatively for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To compare the hospital stay between the thulium fiber laser enucleation of the prostate (TFLEP) and the holmium:YAG laser enucleation of the prostate with Moses technology (m-HoLEP).
Secondary study objectives
To compare catheterization time between cohorts
To compare change in erectile function (IIEF) between cohorts
To compare drop in International Prostate Symptom Score (I-PSS) between cohorts
+10 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: m-HoLEPActive Control1 Intervention
The holmium: yttrium-aluminum-garnet (Ho: YAG) laser is the longest running and most studied laser used to perform this minimally invasive procedure. Holmium laser enucleation of the prostate reduces hospital stay and hemoglobin drop while improving IPSS and quality of life, as well as other positive postoperative outcomes compared to the historical gold standard, transurethral resection of the prostate (TURP). HoLEP has been found to have a better enucleation efficiency rate and may have better hemostatic properties when combined with the modulated pulsed laser energy featured associated with Moses technology (m-HoLEP). Patients will undergo m-HoLEP at the Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Nord-de-l'Île-de-Montréal as a treatment for benign prostate hyperplasia. The surgeon performing m-HoLEP is experienced in m-HoLEP procedures.
Group II: TFLEPActive Control1 Intervention
Thulium fiber laser (TFL) is a novel laser technology that delivers a pulsed laser at a more optimal wavelength and a shallower depth of tissue penetration leading to better hemostatic properties. Patients will undergo thulium fiber laser enucleation of the prostate (TFLEP) at the Centre Hospitalier de l'Université de Montréal (CHUM) as a treatment for benign prostate hyperplasia. The surgeon performing TFLEP is experienced in TFLEP procedures.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Laser enucleation techniques, such as Holmium Laser Enucleation of the Prostate (HoLEP) and Thulium Fiber Laser Enucleation of the Prostate (TFLEP), work by using laser energy to remove excess prostate tissue that causes urinary obstruction. HoLEP, especially with Moses Technology, enhances enucleation efficiency and hemostasis by modulating pulsed laser energy, which reduces bleeding and improves surgical precision. TFLEP uses a thulium fiber laser that operates at an optimal wavelength with shallow tissue penetration, providing superior hemostatic properties. These mechanisms are crucial for patients with BPH as they minimize surgical risks, reduce hospital stays, and improve postoperative outcomes, leading to better symptom relief and quality of life.
[Comparative analysis of the effectiveness of various techniques of endoscopic prostate enucleation in a single center].

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
380 Previous Clinical Trials
131,489 Total Patients Enrolled
~24 spots leftby Dec 2025